The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Real-World Analysis Supports More Frequent Anti-VEGF Dosing for First-Year nAMD
July 21st 2018Researchers found that, contrary to popular opinion, about 80% of patients are receiving at least 7 dosing regimens of anti-VEGF in their first year of treatment, and that frequency has been proven to improve visual acuity.
Canagliflozin Does Not Increase Risk of Amputation, Despite Boxed Warning
June 29th 2018In a comparison of canagliflozin to other SGLT-2 inhibitors and anti-hyperglycemic therapies, the drug was found to decrease hospitalization from heart failure risk, and carry no extra risk for leg or foot amputation.